Treatments for Methamphetamine Abuse

Brackins, Todd; Brahm, Nancy C.; Kissack, Julie C.

doi:10.1177/0897190011426557

Cited by 85 publications

(36 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, active lever responding was increased during the meth-primed reinstatement with 0.3 and 1.0 mg/kg varenicline. An increase in reinstatement behavior is particularly notable, given the importance relapse plays in meth-use disorders (Brackins et al, 2011). That is, varenicline may actually heighten vulnerability to meth relapse in males (reported herein) and females (Pittenger et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in male rats

Pittenger

Barrett

Chou

et al. 2017

Behavioural Brain Research

View full text Add to dashboard Cite

Methamphetamine (meth) addiction is a costly burden to both the individual user and society as a whole. Establishing effective pharmacotherapies to treat meth dependence is needed to help solve this health problem. The study reported herein examined the effects of varenicline, a partial α4β2 and full α7 nicotinic acetylcholine receptor agonist, on meth self-administration and reinstatement in male Sprague-Dawley rats. Following indwelling jugular catheter surgery, rats were either trained to self-administer meth or saline on a variable ratio (VR) 3 schedule of reinforcement. Self-administration sessions (2 hour duration; 19 total sessions) were conducted daily. The effect of varenicline pretreatment on meth and saline self-administration was then determined using a within-study design. All rats received varenicline (0.0, 0.3, 1.0, and 3.0 mg/kg) prior to 4 different test sessions. Dose order was randomly assigned and each test was separated by 2 standard self-administration sessions to assess stability of responding. Fifteen extinction sessions (no meth available) followed the last test. Extinction was followed by meth-primed (0.3 mg/kg IP) reinstatement tests to examine the effect of varenicline on meth-seeking behavior. All rats again received all doses of varenicline over 4 separate reinstatement tests performed on 4 consecutive days. Varenicline did not alter self-administration of meth or saline. Additionally, the 0.3 and 1.0 doses of varenicline non-specifically increased active lever responding during the reinstatement test sessions. This latter finding suggests that varenicline may increase relapse liability and should not be utilized as pharmacotherapy to treat meth dependence.

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in male rats

Pittenger

Barrett

Chou

et al. 2017

Behavioural Brain Research

View full text Add to dashboard Cite

show abstract

“…A key component of effective heroin dependence treatment (Vocci et al, 2005), methadone maintenance reduces risk of mortality (Degenhardt et al, 2011), as well as a range of other health benefits (Amato et al, 2005). In contrast, effective pharmacotherapy options to enhance treatment for stimulant dependence are still in development (Brackins et al, 2011; Ross and Peselow, 2009; Vocci et al, 2005). Psychosocial interventions for stimulant dependence are moderately effective (Vocci and Montoya, 2009) but challenged by poor rates of treatment induction and retention (Shearer, 2007), as observed in our study.…”

Section: Discussionmentioning

confidence: 99%

Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users

Nosyk

Evans

et al. 2014

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Aims Characterize longitudinal patterns of drug use careers and identify determinants of drug use frequency across cohorts of primary heroin, methamphetamine (MA) and cocaine users. Design Pooled analysis of prospective cohort studies. Settings Illicit drug users recruited from community, criminal justice and drug treatment settings in California, USA. Participants We used longitudinal data on from five observational cohort studies featuring primary users of heroin (N=629), cocaine (N=694) and methamphetamine (N=474). The mean duration of follow-up was 20.9 years. Measurements Monthly longitudinal data was arranged according to five health states (incarceration, drug treatment, abstinence, non-daily and daily use). We fitted proportional hazards (PH) frailty models to determine independent differences in successive episode durations. We then executed multi-state Markov (MSM) models to estimate probabilities of transitioning between health states, and the determinants of these transitions. Findings Across primary drug use types, PH frailty models demonstrated durations of daily use diminished in successive episodes over time. MSM models revealed primary stimulant users had more erratic longitudinal patterns of drug use, transitioning more rapidly between periods of treatment, abstinence, non-daily and daily use. MA users exhibited relatively longer durations of high-frequency use. Criminal engagement had a destabilizing effect on health state durations across drug types. Longer incarceration histories were associated with delayed transitions towards cessation. Conclusions PH frailty and MSM modeling techniques provided complementary information on longitudinal patterns of drug abuse. This information can inform clinical practice and policy, and otherwise be used in health economic simulation models, designed to inform resource allocation decisions.

show abstract

“…This review is intended to supplement recent, more comprehensive reviews of pharmacologic treatments for methamphetamine addiction (i.e., Brackins et al, 2011; Brensilver et al, 2013; Rose and Grant, 2008) by distinguishing medications that have been tested clinically for reducing methamphetamine use from medications that may be promising based on their anti-craving effects – yet, clinical trials are ultimately needed. A number of other areas of potential interest to the field are also expanded upon, such as the trends in methamphetamine use/abuse rates, associated costs to the individual and society, and recent debates regarding methamphetamine-related neurocognitive impairments.…”

Section: Introductionmentioning

confidence: 99%

Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature

Courtney

Ray

2014

Drug and Alcohol Dependence

367

255

View full text Add to dashboard Cite

Background-Despite initial reports of a decline in use in the early 2000s, methamphetamine remains a significant public health concern with known neurotoxic and neurocognitive effects to the user. The goal of this review is to update the literature on methamphetamine use and addiction since its assent to peak popularity in 1990s.Methods-Specifically, we first review recent epidemiological reports with a focus on methamphetamine accessibility, changes in use and disorder prevalence rates over time, and accurate estimates of the associated burden of care to the individual and society. Second, we review methamphetamine pharmacology literature with emphasis on the structural and functional neurotoxic effects associated with repeated use of the drug. Third, we briefly outline the findings on methamphetamine-related neurocognitive deficits as assessed via behavioral and neuroimaging paradigms. Lastly, we review the clinical presentation of methamphetamine addiction and the evidence supporting the available psychosocial and pharmacological treatments within the context of an addiction biology framework.Conclusion-Taken together, this review provides a broad-based update of the available literature covering methamphetamine research over the past two decades and concludes with recommendations for future research.

show abstract

Treatments for Methamphetamine Abuse

Cited by 85 publications

References 28 publications

The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in male rats

The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in male rats

Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users

Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature

Contact Info

Product

Resources

About